| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7135465 | BRISTOL MYERS SQUIBB | Sustained release beadlets containing stavudine |
Feb, 2023
(7 months ago) | |
|
US7135465 (Pediatric) | BRISTOL MYERS SQUIBB | Sustained release beadlets containing stavudine |
Aug, 2023
(a month ago) | |
Zerit Xr is owned by Bristol Myers Squibb.
Zerit Xr contains Stavudine.
Zerit Xr has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zerit Xr are:
- US7135465
- US7135465*PED
Zerit Xr was authorised for market use on 31 December, 2002.
Zerit Xr is available in capsule, extended release;oral dosage forms.
Zerit Xr can be used as method for treating hiv-1 infection.
The generics of Zerit Xr are possible to be released after 18 August, 2023.
Drugs and Companies using STAVUDINE ingredient
Market Authorisation Date: 31 December, 2002
Treatment: Method for treating hiv-1 infection
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ZERIT XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic